

ACR レポート

熊本大学大学院医学薬学研究部皮膚機能病態学

熊本大学医学部附属病院皮膚科

熊本大学医学部附属病院形成・再建科

尹 浩信

ACR
2007 Annual Scientific Meeting

November 6-11, 2007

Boston Convention and Exhibition Center

Boston, MA

Sclerodermaに関するAbstracts

- 105 abstracts
- 日本から13 abstracts

ACR Concurrent Session

- Pathogenesis of systemic sclerosis:
Key pathways and molecular targets for therapy

2144. Ghosh AK, et al. Novel function of PPAR γ :
Endogenous anti-fibrotic that ameliorates
murine scleroderma and may be defective in
systemic sclerosis (SSc).

Ligands of PPAR γ \rightarrow adipogenic differentiation

TGF- β \rightarrow PPAR γ expression \downarrow

PPAR γ expression \downarrow in SSc skin

Ligands of PPAR γ ameliorated cutaneous fibrosis
in murine model of scleroderma.

2146. Shiwen X, et al. Imatinib alleviates the pro-fibrotic phenotype of scleroderma fibroblasts.

SSc fibroblasts: c-Abl ↑ , ERK ↑ , matrix proteins ↑
PDGFR blockade: c-Abl ↓ , ERK ↓ ,
type I collagen ↓ , CTGF → in SSc fibroblasts

c-Abl ↑ , ERK ↑ contribute the fibrosis in SSc

ACR Concurrent Session

- Systemic sclerosis, fibrosing syndromes and Raynaud's: Clinical aspects and therapeutics

2163. Chung L, et al. A multi-center placebo-controlled “in-life” study of MQX-503 in patients with Raynaud phenomenon.

2165. Chung L, et al. MQX-503, a novel topical nitroglycerin formulation, improves severity of Raynaud phenomenon in a heterogenous patient population.

- MQX-503はplaceboと比較して、有意に Raynaud condition scoreを改善。
- 早期に有効。
- Secondary Raynaud よりはprimary Raynaud に有効

2167. Pakozdi A, et al. Addition of the short term phosphodiesterase-5 inhibitor Sildenafil to iloprost therapy for scleroderma digital vasculopathy.

- 10例の女性SSc患者(5dcSSc、5lcSSc)
- Sildenafil内服6週後に判定
- 6例に有効
- 5例で潰瘍治癒
- Clinical responderではthermographyにて平均3.6°C指尖温度が上昇